Cite
HARVARD Citation
Margolis, D. et al. (n.d.). Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. Lancet infectious diseases. 15 (10), pp. 1145-1155. [Online].